缺血性脑卒中强化血脂管理上海专家建议  

Shanghai Recommandation of Cholesterol Management in Ischemic Stroke Patients

作　　者：上海卒中学会缺血性脑卒中强化血脂管理上海专家建议专家组 董漪[2] 董强[2] 汪昕[3] 赵玉武 DONG Yi;Shanghai Stroke Association Cholesterol Management Committee Recommandation Writing Group

机构地区：[1]不详 [2]复旦大学附属华山医院 [3]复旦大学附属中山医院 [4]上海交通大学附属上海市第六人民医院

出　　处：《中国临床神经科学》2022年第2期121-128,共8页Chinese Journal of Clinical Neurosciences

摘　　要：中国缺血性脑卒中以大动脉粥样硬化型为主,约占45%。同时,低密度脂蛋白胆固醇(LDL-C)是缺血性脑卒中的独立危险因素。在动脉粥样硬化的发生发展过程中,LDL-C升高是最关键的因素之一。越来越多的临床研究提示,在规范脑卒中二级预防的基础上进一步强化降脂对预防脑卒中再发仍有临床意义。因此本专家组建议拟结合中国脑卒中后患者管理的现状,系统性分析既往研究结果,提出高危人群识别、强化降脂的临床路径及随访流程,拟进一步强化调脂药物的使用,提高脑卒中患者发病后的LDL-C达标率,为降低缺血性脑卒中患者脑卒中和其他血管事件复发的风险提出新思路。The large artery atherosclerosis was the major cause of ischemic stroke in China.About 45%of ischemic stroke was related to this cause.Low density lipoprotein cholesterol(LDL-C)was confirmed as the independent risk factor to ischemic stroke,which plays an important role in atherosclerosis changes.More and more clinical trials suggest that it is still of clinical significance to further strengthen lipid-lowering on the basis of standardizing secondary prevention of stroke.Therefore,the experts of Shanghai Stroke Association published Shanghai Recommendations of Cholestrol Management in Ischemic Stroke Patients.The recommendation emphasized that the cholesterol management is critical for long-term prognosis and secondary prevention of ischemic stroke,and stratified the risk level,and recommendation on assessment.And the recommendation also evaluated the potential impact of novel lipid-lowering agents in stroke patients.

关 键 词：脑卒中 血脂 低密度脂蛋白胆固醇 他汀类药物 非他汀类药物 危险因素 

分 类 号：R743[医药卫生—神经病学与精神病学]